What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?

The best choice for 2nd line treatment after progression on osimertinib depends on multiple factors. If a patient has progressive disease in only 1 area while all other areas are well controlled, you could consider local therapy (SBRT or EBRT) to that one area of progression, and continue the osimer...